Marc Beer: The Chairman of Biotechnology Leading Us to the Future of Medicine

Marc Beer is an American businessman who recently became Chairman of the Board for LumeNXT. According to Prnewswire.com, LumeNXT is a privately-held company that develops a surgical illumination product line designed for minimally invasive surgeries. Marc Beer has more than 25 years of experience in the commercialization and development of biotechnology, devices, diagnostics, and pharmaceuticals. Marc stated in a recent interview that he is proud to work with the engineers and surgeons associated with LumeNXT. He also believes the company will have more of an impact when minimal invasive surgeries are more common. Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues

The Co-Founder of LumeNXT Paul Rhyne praises Marc’s ability to lead multiple companies successfully. Rhyne also believes that Marc’s experience is a strong asset to his organization. In 2016 Marc Beer raised $42 million dollars as the Founding Chairman of the Board for Renovia, Inc. Renovia, Inc is a company that delivers digital therapeutic and diagnostic devices for women with pelvic floor disorder. Before his term at Renovia, Inc. Marc Beer was a Founding Chairman at Minerva Neurosciences Inc. Minerva is a clinical biopharmaceutical company that develops and test medicines for Parkinson’s Disease, mood disorders, insomnia, major depressive disorders, and schizophrenia.

Marc Beer has also served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board and a member of the Mass Life Science Board of the Commonwealth of Massachusetts. He was the Vice President of Global Marketing at Genzyme and Founding Chairman of the board of Good Start Genetics, Inc. Marc was once a CEO of ViaCell and on the Board of Directors of Erytech Pharma. He also worked in marketing and sales at Abbott Laboratories. Marc is also a member of the Graduate Studies and Research Advisory Council of Notre Dame University and a B.S. from Miami University (Oxford, OH).

Today, Marc Beer has yet another opportunity to successfully lead a business in the growing biotechnology field. He has a track record of successful ventures into businesses that are on the cutting edge of science and technology. His peers acknowledge the skills and expertise he has acquired within the industry. In an earlier 2018 interview, Marc stated that his key to success was the ability to hire and organize the best people in their field. He also noted that to generate the best product possible, you have to continuously scrutinize the product. Marc Beer is truly a visionary that puts his best efforts and talents to work productively. His accomplishments leave us all wondering what’s next for this entrepreneur?

Renovia Gets A Major Boost After Marc Beer Closes $42 Million

Renovia Inc, set to move forward with several pelvic floor disorder products after its founding CEO sourced $42 million in Series B round and venture debt. He managed to raise $32 million in Series B and $10 million in venture debt. Renovia Inc., is a pharmaceutical startup that is focused on finding treatment for pelvic floor disorders in women.

Renovia is developing diagnostic and therapeutic products that will put pelvic floor cases to rest. According to a research, over 250 million women across the world have urinary incontinence, one type of pelvic floor disorders. One of the first products Renovia developed, Leva, was approved in April by FDA.

The Series B round of financing was conducted by Perceptive Advisors and Ascension Ventures which are based in New York and Missouri respectively. The funds will be used to develop four more therapeutic and diagnostic products including a modern generation of the Leva device.

Marc Beer expressed his excitement for the support he garnered from leading investors in the healthcare sector. In a statement, he stated that the supportive investors share the same vision with his company to improve the lives of women suffering from pelvic floor disorders around the world. He looks to avail valuable data to their customers that will inform new treatment options, drive greater knowledge and ultimately, improve understanding of the disorders. In the long-run, long-term healthcare costs will be reduced.

Marc Beer has led a successful career in the healthcare industry working in prominent companies and establishing companies. He served at OvaScience as a strategic consultant. OvaScience had shown interests of merging with Millendo Therapeutics. Learn more: https://gazetteday.com/2018/10/marc-beer-funding-renovia/

A Look at the Career Life of Marc Beer

Marc Beer is the co-founder and CEO of the Boston-based medtech company. He brings over 25 years of development and commercialization experience in the pharmaceutical, biotechnology, diagnostic and device industries. He earned his BS degree from Miami University, OHIO. He has worked at several companies and founded a couple of companies that thrived in the industry.

As the Founding CEO of ViaCell, he led the biotechnology company from inception to when it had over 300 employees and went public. The company was later acquired by PerkinElmer in 2007. At the same time, Beer was a member of Erytech Pharma’s Board of Directors. Mr. Beer was the Founding Chairman of the board of directors as well as chairman of the compensation committee of Good Start Genetics. He serves in various capacities at Minerva Neurosciences. He sits in the Miami University Business Advisory Council as a member. Formerly, he sat in the Notre Dame Research and Commercialization Advisory Committee as well as Norte Dame Graduate Studies Research and Advisory Council as a member. The work background of Marc Beer is extensive. His dedicated service in the industry has promoted the industry significantly.